Non-small cell lung cancer
Conditions
Interventions
PET/CT 2 days after erlotinib administration
Sponsors
Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) NSCLC 2) no history of treatment of EGFR-TKI 3) At least one measurable lesion 4) Age>20 years 5) Performance status(PS) of 0 to 2 6) Written informed consent
Exclusion criteria
Exclusion criteria: 1)History of radiation therapy for primary site 2)Severe infection 3)Bowel obstruction 4)Interstitioal pneumonia or lung fibrosis 5)History of any thoracic radiation therapy 6)Active concomitant malignancy 7)Sever heart disease 8)No regulatory condition because of psychological disease 9)Pregnant women or somen willing child-bearing 10)inadequate condition siagnosed by primary physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between uptake of FDG 2 days after the erlotinib administration and tumor size on CT | — |
Secondary
| Measure | Time frame |
|---|---|
| OS, PFS | — |
Countries
Japan
Contacts
Public ContactIsao Tachibana
Osaka University Graduate School of Medicine Department of Respiratory Medicine, Allergy and Rheumatic Diseases
Outcome results
None listed